Advisory Alpha’s Jazz Pharmaceuticals JAZZ Stock Holding History

Advisory Alpha’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-85	Closed	-$12.4K	–	775
2019 Q4	$12.4K	Buy	+85	New	+$11.6K	﹤0.01%	473

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Advisory Alpha's JAZZ Position: Q1 2020 in Review

Advisory Alpha sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2020, closing a stake of 85 shares — an estimated $12.4K sold.

Advisory Alpha first reported a position in JAZZ in Q4 2019 and held it in 1 quarter. The position peaked at $12.4K in Q4 2019. 407 funds tracked by Wall St. Rank hold JAZZ as of Q1 2020.

Advisory Alpha reported no remaining Jazz Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Advisory Alpha sold 85 Jazz Pharmaceuticals shares in Q1 2020, an estimated $12.4K.
Advisory Alpha first reported a position in Jazz Pharmaceuticals in Q4 2019 and held it in 1 quarter.
Advisory Alpha's Jazz Pharmaceuticals position peaked at $12.4K in Q4 2019.
407 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2020.

Based on Advisory Alpha's 13F filing for Q1 2020, filed 29 Apr 2020.